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OBJECTIVEdTo investigate the relationship between different degrees of subclinical myo
cardial necrosis, glycemic control, and long term adverse clinical outcomes within a stable pa
tient population with diabetes mellitus.
RESEARCH DESIGN AND METHODSdWe examined 1,275 stable patients with di
abetes mellitus undergoing elective diagnostic coronary angiography with cardiac troponin I
(cTnI) levels below the diagnostic cut off for deﬁningmyocardial infarction (MI) (,0.03 ng/mL).
The relationship of subclinical myocardial necrosis (cTnI 0.009 0.029 ng/mL) with incident
major adverse cardiovascular events (MACE; deﬁned as any death, MI, or stroke) over 3 years
of follow up was examined.
RESULTSdSubclinical myocardial necrosis was observed in 22% of patients. A strong asso
ciation was observed between themagnitude of subclinical myocardial necrosis and risk of 3 year
incident MACE (hazard ratio, 1.98; 95% conﬁdence interval, 1.48 2.65; P , 0.001) and
remained statistically signiﬁcant even after adjustment for traditional risk factors, high sensitivity
C reactive protein, and creatinine clearance. Only a weak correlation was observed between the
presence of subclinical myocardial necrosis and either glycemic control (r = 0.06; P = 0.044 for
hemoglobin A1c versus cTnI) or insulin resistance (r = 0.04; P = 0.094 for glucose to insulin
ratio versus cTnI).
CONCLUSIONSdThe presence of detectable subclinical myocardial necrosis in stable
patients with diabetes mellitus is associated with heightened long term risk for MACE, indepen
dent of traditional risk factors and glycemic control.
Detection of systemic levels of cardiac 
troponin is associated with the 
presence of ongoing myocardial
necrosis and fulﬁlls the contemporary
deﬁnition of myocardial infarction (MI)
in the presence of ischemic symptoms (1).
However, a minimal increase in cardiac
troponin levels below the diagnostic
range often provides clinical challenges,
particularly in stable ambulatory patients
without overt signs and symptoms sug
gestive of underlying ischemia and nor
mal renal function (2). As biochemical
assays become more and more sensitive,
the ability to detect minimal myocardial
damage may allow risk assessment in sta
ble cardiac patients beyond the acute
setting (3).
We recently have demonstrated that
such presence of subclinical myocardial
necrosis was associated with adverse long
term cardiovascular risks in stable patients
undergoing elective coronary angiography
(4). These ﬁndings were reported in dia
betic and nondiabetic patients with and
without coronary artery disease and heart
failure.We sought to examine the prognos
tic signiﬁcance of detectable subclinical
myocardial necrosis in the setting of diabe
tes mellitus, particularly to examine its re
lationship with underlying glycemic
control.
RESEARCH DESIGN AND
METHODS The Cleveland Clinic
GeneBank study is a large, prospective,
cohort study that established a well
characterized clinical repository with
clinical data and longitudinal outcomes
from consenting subjects undergoing
elective diagnostic coronary angiography
from 2001 to 2006. All GeneBank partic
ipants gave written informed consent
approved by the Cleveland Clinic Insti
tutional Review Board. All blood samples
were collected at the time of cardiac
catheterization procedure. This analysis
included a cohort of 1,275 consecutive
consenting subjects with a clinical diagno
sis of diabetes mellitus without clinical
evidence of acute coronary syndrome at
the time of enrollment with 3 year follow
up data. These patients underwent elective
diagnostic coronary angiography within 1
year of attending outpatient appointments,
scheduled coronary computed tomogra
phy angiogram scans, or computed tomog
raphy scans within 1 year of scheduled
blood draws. The various reasons for the
elective coronary angiography include
(subjects could have more than one reason
per person) the following: history of pos
itive or indeterminate stress test (50%);
evaluation for possible ischemic causes of
symptoms (68%); preoperative evaluation
(10%); and history of cardiomyopathy
(3%). Subjects included were only those
with cardiac troponin I (cTnI),0.03ng/mL,
no history of revascularization within 30
days before enrollment, and at least 3 years
of adjudicated follow up data. The diag
nosis of diabetes mellitus was determined
based on the latest guideline recommen
dations as clinical history of diabetes mel
litus or fasting glucose $126 mg/dL or
hemoglobin A1c (HbA1c) $6.5% at the
time of enrollment (5).
Plasma levels of cTnI were measured 
using the STAT Troponin I assay (Abbott 
laboratories, Abbott Park, IL) ina research 
based immunoanalyzer that provides a 
three decimal point readout from venous 
blood samples collected by EDTA tubes. 
This assay provides highly sensitive analyt 
ical measuremem of cTnl with a reported 
limit of detection reaching 0.009 nglmL in 
the literature ( 4) and a diagnostic cut off of 
0.03 nglmL for MI defined by the upper 
limit of normal (99th percemile cut off 
with 10% coefficiem of variation). Based 
on the analytical characteristics of the 
cTnl assay, we defined subclinical myocar 
dial necrosis as cTnl 0.009 0.029 nglmL 
(above level of detection). High sensitivity 
C reactive protein (hsCRP), HbA1c , glu 
cose, insulin, creatinine, and fasting lipid 
profiles all were measured simultaneously 
with the cTnl assay using the same analysis 
platform. Treating physicians and adjudi 
cation commiuee were blinded to the re 
sults of cTnl. 
We defined coronary angiography as 
any clinical history of MI, percutaneous 
coronary intervention, coronary artery 
by pass graft, or angiographic evidence of 
significantstenosis ( 50%) in one or more 
major coronary arteries. Dyslipidemia was 
defined as LDL cholesterol > 130 mgldL, 
HDL cholesterol <50 mgldL, triglycerides 
> 150 mgldL, or the use of lipid lowering 
agents. An estimate of creatinine clearance 
(eCrO) was calculated using the Cockcroft 
Gault equation, because a large majority of 
subjects had relatively preserved renal 
function. Adjudicated outcomes were 
prospectively ascertained over the ensuing 
3 years for all subjects after enrollmem. 
Maj or adverse cardiovascular event 
(MACE) was defined as death, nonfatal MI, 
or nonfatal stroke after enrollmem. Non 
fatal MI was defined as patients that re 
mained alive over the follow up period 
of 3 years and met the universal definition 
of MI, which is defined as a documented 
increase in cardiac biomarker in conjunc 
tion with evidence of myocardial ische 
mia (1). Nonfatal stroke in this cohort 
was defined as patients with a clinical 
diagnosis of rapid loss of brain function 
attributable to blood flow disturbance to 
the brain with accompanying imaging 
techniques or records of confirmed diag 
nosis who remained alive over the follow 
up period of 3 years. All cause death was 
ascertained by follow up (1 and 3 year) 
telephone interviews, Social Security
Death Index that was assessed periodi 
cally after enrollment, official hospital 
record, or death certificate. 
The Student t test or Wilcoxon rank 
sum test for continuous variables and x2 
test for categorical variables were used to 
examine the difference between the 
groups. Unadjusted trends (adjusted for 
age and sex only) for all cause mortality 
rates as well as nonfatal Ml/stroke rates 
with increasing tertiles of cTnI were eval 
uated with the Cochran Armitage test 
using a time to event approach. Adjust 
ments were made for individual tradi 
tional cardiac risk factor, Framingham 
risk factors (including age, sex, cigarette 
smoking, LDL cholesterol, HDL choles 
terol, and systolic blood pressure) plus 
log transformed hsCRP, and CrCl to pre 
diet incident 3 year MACE risks. Kaplan 
Meier analysis with Cox proportional 
hazards regression was used for time 
to event analysis to determine hazard ra 
tio (HR) and 95% confidence intervals 
(95% Cis) for MACE. Levels of cTnI 
then were adjusted for traditional 
Table I-Baseline characteristics 
cTnl range (nglml) 
Demographics and clinical data 
Age (years) 
Male(%) 
Systolic blood pressure 
History of hy p e n ension (%) 
History of hean failure (%) 
Cigarette smoking (former/current %) 
Previous myocardial infarction(%) 
Previous revascularization (%) 
Maximal stenosis  50% (%) 
Number of coronary vessel disease 
None(%) 
One(%) 
Two(%) 
Three(%) 
HbA1c (%) 
Laboratory data 
Fasting LDL cholesterol (mgfdl) 
coronary angiography risk factors in 
a multivariable model including Framing 
ham risk factors, log transformed hsCRP, 
and CrCl. We confirmed that both the 
proportionality hazards and linearity as 
sumptions were met. All analyses were 
performed using R 2.10.1 (Vienna, Aus 
tria). P < 0.05 was considered statistically 
significant. The authors had full access 
to all of the de identified data in the study 
and take responsibility for the integrity 
of the data and the accuracy of the data 
analysis. 
R E S U L T S  In our study cohort of 
1,275 subjects, 22% of subjects had 
evidence of subclinical myocardial necro 
sis (with 34% detectable but in the range 
of 0.001 0.008 nglmL). The evem num 
bers for MACE in our cohort over the 
3 year follow up were as follows: all 
cause death, 129/1,275; nonfatal MI, 62/ 
1,275; and nonfatal stroke, 31/1,275. 
Subclinical myocardial necrosis 
No (n = 989) Yes (n = 286) 
<0.01 0.01 0.03 
64 ::!: 10 67 ::!: 10 
59 70 
136 ::!: 21 138 ::!: 24 
77 82 
16 38 
63 68 
31 53 
31 40 
77 87 
23 14 
19 13 
20 21 
38 52 
6.7 (6.1 7 7) 7.0 (6 4 8) 
94 (76 114) 92 (75 112) 
p 
<0.001 
0.002 
0.205 
0.111 
<0.001 
0.17 
<0.001 
0003 
<0.001 
0.001 
0.017 
0606 
<0.001 
0006 
Fasting HDL cholesterol (mgtdl) 32.9 (27.5 40.1) 31.4 (25 7 38.1) 
0.387 
0.002 
0.508 Fasting triglycerides (mgfdl) 128 (90 187) 
hsCRP (mgfl) 2.4 (11 5 9) 
CrCI (ml./min/1. 73m 2) 104 (78 132) 
Baseline medications 
Aspirin(%) 75 
Statin (%) 64 
ACE inhibitors (%) 57 
Beta blockers (%) 64 
Insulin(%) 19 
Oral glucose lowering drugs(%) 42 
Values expressed in mean :!: SD or median (interquartile range). 
126 (90 172) 
36(1.5 70) 
84 (61 112) 
72 
62 
70 
67 
23 
44 
<0.001 
<0.001 
0.442 
0.58 
<0.001 
0.358 
0085 
0.466 
Baseline characteristics of the study pop
ulation are shown in Table 1 and are strat
iﬁed according to presence or absence of
subclinical myocardial necrosis. Patients
with evidence of subclinical myocardial
necrosis were more likely to be older,
with more cardiovascular risk factors
and history of heart failure, and with
slightly lower renal function at baseline.
Subjects with evidence of subclinical
myocardial necrosis were associated with
an increased 3 year risk of death (HR,
2.39; 95% CI, 1.68 3.40; P , 0.001),
nonfatal MI or stroke (HR, 1.70; 1.09
2.66; P = 0.019), and MACE (HR, 1.98;
1.48 2.65; P , 0.001) (Fig. 1). The risk
prediction appeared to be log linear as de
tectable cTnI levels increased (Fig. 2).
After adjusting for traditional risk factors,
including Framingham risk factors,
hsCRP, and eCrCl, evidence of subclinical
myocardial necrosis within stable cardiac
diabetic patients remained a signiﬁcant
risk of incident MACE over the ensuing
3 years (HR, 1.48; 1.08 2.01; P = 0.013;
Table 2).
A weak correlation was observed
between the presence of subclinical myo
cardial necrosis and either glycemic con
trol (r = 0.06 and P = 0.044 for HbA1c
versus cTnI) or insulin resistance (r = 0.04
and P = 0.094 for glucose to insulin ratio
versus cTnI). Adjustments with either met
abolic parameters had little impact on the
prognostic value of detectable subclinical
myocardial necrosis within the study co
hort. Figure 3 illustrates similar risk predic
tion for major adverse clinical events at
3 years according to subclinical myocardial
necrosis status stratiﬁed by on treatment
HbA1c using a cut off of 6.5%. The cTnI
levels demonstrated no signiﬁcant interac
tion with statin use or HbA1c levels (P for
interaction$0.20).
CONCLUSIONS The major ﬁnding
of our study is the demonstration that the
presence of subclinical myocardial necro
sis in a respectable proportion of stable
patients with diabetes mellitus has height
ened long term adverse cardiovascular
event risk. We further demonstrated
that such risk may be independent of
underlying glycemic control. These ﬁnd
ings would appear to imply that any
detectable cTnI level should warrant con
sideration for more globally aggressive
risk reduction efforts, including closer
evaluation and long term monitoring,
and such intervention efforts may focus
beyond glycemic control measures.
The concept of diabetes mellitus
being a “coronary artery disease risk
equivalent” has been suggested in several
important studies (6 8) and even for
those subjects with suspected acute coro
nary syndrome but with “normal” cardiac
troponin levels (9). Guideline recommen
dations for routine aspirin prescription and
secondary prevention therefore have been
proposed (10 12). However, recent analy
ses have directly challenged such assertions
(13,14). It is therefore conceivable that dif
ferences in risk proﬁles of patients with
diabetes mellitus may warrant different in
dications of preventive interventions (5).
Using the latest guideline recommenda
tions for the deﬁnition and classiﬁcation
of diabetes mellitus including HbA1c as
sessments (15), the current study provides
Figure 1dKaplan Meier analysis for 3 year major adverse clinical events, stratiﬁed according
to subclinical myocardial necrosis status (rounded to the nearest 0.001 ng/mL).
Figure 2dCubic spline curve of HRs for major adverse clinical events at 3 years with cTnI levels.

The strength of the current study is
the ability to determine the future cardiac
risk in a broad clinical population of
patients with contemporary deﬁnition
and management of diabetes mellitus in
which cardiac troponin measurements
are not routinely performed or clinically
indicated at this time. However, the fact
that all subjects were referred for coronary
angiography, albeit electively, and that
many had relatively preserved renal func
tion, also may represent some degree of
selection bias and may not be fully repre
sentative of the broad population of pa
tients with diabetes mellitus in clinical
practices. Nevertheless, the fact that we
only included those with no revasculari
zation performed within 30 days after
enrollment ensured a population deemed
“medically managed” for their cardiac
conditions. It also should be noted that
our study was limited to a single measure
ment and further work with serial mea
surements is needed to substantiate the
variability of the marker for risk stratiﬁca
tion. Moreover, serial measures will be
useful because it is unclear what impact
various interventions have on cTnI levels
in the subclinical range in these subjects
(24). It also is worth noting that limita
tions of our assays cannot precisely deﬁne
subclinical myocardial necrosis in the
lower range of 0.001 0.008 ng/mL, al
though the diagnostic accuracies of those
with current deﬁnition of subclinical
myocardial necrosis are certain. Most im
portantly, further studies are needed to
determine if the presence of subclinical
myocardial necrosis represents an under
lying process that can be targeted for in
terventions. The presence of detectable
subclinical myocardial necrosis in stable
patients with diabetes mellitus is associ
ated with heightened long term risk for
MACE, independent of traditional risk
factors and glycemic control.
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